Correlation Between Hookipa Pharma and Virpax Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Hookipa Pharma and Virpax Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Hookipa Pharma and Virpax Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Hookipa Pharma and Virpax Pharmaceuticals, you can compare the effects of market volatilities on Hookipa Pharma and Virpax Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Hookipa Pharma with a short position of Virpax Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Hookipa Pharma and Virpax Pharmaceuticals.

Diversification Opportunities for Hookipa Pharma and Virpax Pharmaceuticals

0.77
  Correlation Coefficient

Poor diversification

The 3 months correlation between Hookipa and Virpax is 0.77. Overlapping area represents the amount of risk that can be diversified away by holding Hookipa Pharma and Virpax Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Virpax Pharmaceuticals and Hookipa Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Hookipa Pharma are associated (or correlated) with Virpax Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Virpax Pharmaceuticals has no effect on the direction of Hookipa Pharma i.e., Hookipa Pharma and Virpax Pharmaceuticals go up and down completely randomly.

Pair Corralation between Hookipa Pharma and Virpax Pharmaceuticals

Given the investment horizon of 90 days Hookipa Pharma is expected to under-perform the Virpax Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Hookipa Pharma is 2.21 times less risky than Virpax Pharmaceuticals. The stock trades about -0.29 of its potential returns per unit of risk. The Virpax Pharmaceuticals is currently generating about -0.09 of returns per unit of risk over similar time horizon. If you would invest  68.00  in Virpax Pharmaceuticals on September 27, 2024 and sell it today you would lose (35.00) from holding Virpax Pharmaceuticals or give up 51.47% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Hookipa Pharma  vs.  Virpax Pharmaceuticals

 Performance 
       Timeline  
Hookipa Pharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Hookipa Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.
Virpax Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Virpax Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Hookipa Pharma and Virpax Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Hookipa Pharma and Virpax Pharmaceuticals

The main advantage of trading using opposite Hookipa Pharma and Virpax Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Hookipa Pharma position performs unexpectedly, Virpax Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Virpax Pharmaceuticals will offset losses from the drop in Virpax Pharmaceuticals' long position.
The idea behind Hookipa Pharma and Virpax Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Other Complementary Tools

Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
CEOs Directory
Screen CEOs from public companies around the world
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.